Winner named in Coolest Thing Made in Iowa contest
The John Deere CP770 Cotton Picker was announced as the second winner of the Coolest Thing Made in Iowa contest during the Iowa Association of Business and Industry Taking Care of Business Conference on Wednesday.
The CP770 Cotton Picker was introduced in 2021 and is a leader in cotton harvesting technology. The picker is larger, faster, and more efficient than previous models. In addition, the model features smart tech that offers guidance to farmers in the fields.
New law helps clear the way for birthing centers in Iowa
Following the announcement, John Deere released this statement.
Dedicated employees at Des Moines Works have been assembling cotton pickers in Ankeny since 1950,' said Rosalind Fox, factory manager. 'We will forever innovate on behalf of our customers, committed to delivering the world's most advanced cotton harvesting equipment to their fields. Every day, our employees arrive with pride, eager to serve our customers. This award belongs to everyone who has contributed to the success of the CP770, from concept to fabrication, assembly to delivery, and everything in between. We all continue to push boundaries to better serve farmers around the world.
Rosalind Fox, John Deere Des Moines factory manager
This is the second year of the Coolest Thing Made in Iowa contest. The Vermeer ZR5-1200 self-propelled baler won during the first year in 2024. The Iowa Association of Business and Industry says the contest is successful and plans to bring it back next year.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Guess?, Inc. (NYSE: GES) will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, on Wednesday, August 27, 2025. The financial results will be accessible at via the 'Investor Relations' link. In light of the pending take-private transaction announced separately today, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. At May 3, 2025, the Company directly operated 1,074 retail stores in Europe, the Americas and Asia. The Company's partners and distributors operated 527 additional retail stores worldwide. At May 3, 2025, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit
Business Wire
an hour ago
- Business Wire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27 th Annual Global Investment Conference in New York City, September 8-10, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. ('RenovoRx' or the 'Company') (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025. Mr. Bagai will be conducting a virtual presentation, which will be available for the duration of the conference, and afterwards on the Company's IR website at Mr. Bagai will discuss RenovoRx's ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai's presentation will also highlight the latest developments in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee's (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52 nd death. The TIGeR-PaC trial is evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC). Presentation Details: To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@ About RenovoCath Based on its FDA clearance, RenovoCath ® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ('IFU'), please see: About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner. For more information, visit Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company's management made in connection therewith and at the investor conference described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath ® or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as 'may,' 'expects,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'forecasts,' 'estimates,' 'intends,' and 'potential,' or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Gizmodo
an hour ago
- Gizmodo
John Deere Hit With Layoffs Amidst Trump's Idiotic Tariffs
Donald Trump's tariff policies are generating billions of dollars for the federal government by sucking it out of American businesses via import duties. Some companies seem to be feeling downstream impacts from the government's unconventional new policies, and it may even be resulting in job losses for the sort of companies that sell to Trump's base. John Deere, the tractor seller, recently announced a raft of layoffs, but right before doing that, it held an unfortunate earnings call during which executives revealed that the company had seen a downturn in profits. Some of that downturn, the call seemed to suggest, could be credited to the climate of uncertainty created by the administration's tariff regime. The Des Moines Register reports: In its earnings report, the company noted that President Donald Trump's tariffs have added to the woes of farm-equipment makers who already were grappling with slow demand. Farmers are opting to rent machinery instead of buying. 'Tariff uncertainty and deflated commodity prices have made farmers increasingly cautious in spending decisions and more hesitant to accept higher machinery prices,' said CFRA Research analyst Jonathan Sakraida. The New Republic reports that, during the company's recent earnings call, Cory Reed, president of John Deere's Worldwide Agriculture and Turf Division, noted that the tariffs were a factor in buying decisions. 'If you have customers that are concerned about what their end markets are going to look like in a tariff environment, they're waiting to see the outcomes of what these trade deals look like,' Reed said. In other words, once again, demographics that Trump claimed he would help (factory workers and farmers) seem to be getting shafted by his policies. The layoffs at John Deere, which were announced on Aug. 18th, will impact 71 workers at its foundry in Iowa and another 167 workers at various locations in Illinois, the Register writes. While the side effects of Trump's tariff regime haven't been quite as apocalyptic as some analysts initially imagined, the economy isn't doing great, and small business owners are clearly feeling the pain from the new economic order. Indeed, recent lawsuits filed by small businesses against the Trump administration have thrown into question the very legal basis of his policies. As we pointed out earlier this month, if the tariffs are deemed illegal in a court of law, it's likely that the government will have to pay back all of that tariff revenue to the businesses it came from. This would be a terrible humiliation for the White House, a logistical nightmare, and a financial disaster for the federal government. Somehow, it's still sorta funny to imagine it happening.
